K_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":696174376,"tweetId":"696174376","gmtCreate":1640656213980,"gmtModify":1640656703694,"author":{"id":3586129577058331,"idStr":"3586129577058331","authorId":3586129577058331,"authorIdStr":"3586129577058331","name":"1a327e37","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>K</body></html>","htmlText":"<html><head></head><body>K</body></html>","text":"K","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696174376","repostId":1156481741,"repostType":4,"repost":{"id":"1156481741","kind":"news","pubTimestamp":1640652473,"share":"https://www.laohu8.com/m/news/1156481741?lang=&edition=full","pubTime":"2021-12-28 08:47","market":"us","language":"en","title":"Is Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?","url":"https://stock-news.laohu8.com/highlight/detail?id=1156481741","media":"Investors","summary":"The Food and Drug Administration authorized Merck's (MRK) antiviral Covid pill, molnupiravir. But Me","content":"The Food and Drug Administration authorized&nbsp;Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.\nThe FDA authorized the Ridgeback Biotherapeutics-partnered pill for emergency use when other options aren't available or appropriate.Pfizer(PFE) also gained authorization for its two-pill regimen, Paxlovid. Paxlovid proved more effective in clinical testing. Further, molnupiravir carries a cancer risk and could lead to birth defects in unborn children.\nMerck's molnupiravir cut the risk of Covid-related hospitalizations or death by 30% when patients began treatment within five days of symptoms appearing. Paxlovid reduced the same risk by 89% for patients who began treatment within three days of symptom onset.\nMerck stock is well off highs it achieved in November. Bullishly, the company beat third-quarter expectations and offered an upbeat 2021 outlook that didn't include the potential impact of the antiviral pill. Molnupiravir is also allowed in the U.K. and Japan.\nMerck expects to produce 10 million courses of molnupiravir this year and at least 20 million in 2022. It has supply agreements in place with more than 30 countries worldwide, including the U.S.\nSo, all in all, is Merck stock a buy or a sell right now?\nMerck Stock Fundamentals: Sales Top\nDuring the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.\nMerck also provided guidance following its&nbsp;Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.\nThe company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.\nBut revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.\nOverall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.\nIn the current quarter, analysts polled by FactSet expect Merck to earn $1.52 per share on $13.16 billion in sales. On a year-over-year basis, earnings would surge about 21% and sales would rise north of 5%.\nWhat Do Annual Metrics Say About Merck?\nAs Dec. 27, Merck stock was down slightly for the year. Shares recently hit at least a three-decade high, but have since tumbled.\nLast year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.\nFor 2021, analysts expect sales to rise a fraction to $48.44 billion. Income is projected to inch 2.8% higher to $5.82 a share. That follows 14% growth in 2020.\nThe stock ranks 6th by&nbsp;Composite Rating&nbsp;in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks No. 51 out of 197 groups tracked by Investor's Business Daily.\nTechnical Analysis Of The Pharmaceutical Company\nMerck stock has a&nbsp;Composite Rating&nbsp;of 81 out of a best-possible 99. The CR is a measure of a stock's key growth metrics over the past 12 months. This puts Merck stock within the top 19% of all stocks, regardless of industry group.\nShares also have a&nbsp;Relative Strength Rating&nbsp;of 57, reflecting the 12-month performance of Merck stock. This means the pharmaceutical stock ranks beneath the top one-third all stocks in terms of performance.\nIt's also key to watch chart patterns. Merck stock broke out of a&nbsp;flat base&nbsp;with abuy point&nbsp;at 79.33 on Oct. 1, according to&nbsp;MarketSmith.com. But shares fell as much as 7% below their entry on Nov. 30. That triggered a sell signal. Investors are&nbsp;encouraged to sell&nbsp;when a stock is 7%-8% below its entry.\nMerck stock also recently undercut its&nbsp;50-day&nbsp;and&nbsp;200-day&nbsp;moving averages. Both are sell signals.\nMerck Stock News: Merck Grabs Covid Deal\nMerck's molnupiravir is now authorized in the U.S., U.K. and Japan.\nIn addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and&nbsp;Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.\nAnalysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from&nbsp;Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and&nbsp;Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.\nBut there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.\nBearishly, the FDA placed a study testing an HIV prevention drug, islatravir, on clinical hold. Several patients showed decreased in key immune cells. Merck and&nbsp;Gilead Sciences(GILD) also decided to stop testing a regimen of islatravir and Gilead's lenacapavir in HIV patients.\nMerck also recently finished acquiring Acceleron.\nIn early March, President Joe Biden announced Merck would helpJohnson &amp; Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.\nIs Merck Stock A Buy Now?\nBased on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.\nThere are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.\nStill, big stocks like Merck can add gains without hitting massive growth streaks.","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 08:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/merck-stock-buy-now/?src=A00220>Investors</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nThe Food and Drug Administration authorized Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.\nThe FDA authorized the Ridgeback Biotherapeutics-partnered pill ...\n\n<a href=\"https://www.investors.com/news/technology/merck-stock-buy-now/?src=A00220\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.investors.com/news/technology/merck-stock-buy-now/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156481741","content_text":"The Food and Drug Administration authorized Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.\nThe FDA authorized the Ridgeback Biotherapeutics-partnered pill for emergency use when other options aren't available or appropriate.Pfizer(PFE) also gained authorization for its two-pill regimen, Paxlovid. Paxlovid proved more effective in clinical testing. Further, molnupiravir carries a cancer risk and could lead to birth defects in unborn children.\nMerck's molnupiravir cut the risk of Covid-related hospitalizations or death by 30% when patients began treatment within five days of symptoms appearing. Paxlovid reduced the same risk by 89% for patients who began treatment within three days of symptom onset.\nMerck stock is well off highs it achieved in November. Bullishly, the company beat third-quarter expectations and offered an upbeat 2021 outlook that didn't include the potential impact of the antiviral pill. Molnupiravir is also allowed in the U.K. and Japan.\nMerck expects to produce 10 million courses of molnupiravir this year and at least 20 million in 2022. It has supply agreements in place with more than 30 countries worldwide, including the U.S.\nSo, all in all, is Merck stock a buy or a sell right now?\nMerck Stock Fundamentals: Sales Top\nDuring the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.\nMerck also provided guidance following its Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.\nThe company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.\nBut revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.\nOverall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.\nIn the current quarter, analysts polled by FactSet expect Merck to earn $1.52 per share on $13.16 billion in sales. On a year-over-year basis, earnings would surge about 21% and sales would rise north of 5%.\nWhat Do Annual Metrics Say About Merck?\nAs Dec. 27, Merck stock was down slightly for the year. Shares recently hit at least a three-decade high, but have since tumbled.\nLast year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.\nFor 2021, analysts expect sales to rise a fraction to $48.44 billion. Income is projected to inch 2.8% higher to $5.82 a share. That follows 14% growth in 2020.\nThe stock ranks 6th by Composite Rating in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks No. 51 out of 197 groups tracked by Investor's Business Daily.\nTechnical Analysis Of The Pharmaceutical Company\nMerck stock has a Composite Rating of 81 out of a best-possible 99. The CR is a measure of a stock's key growth metrics over the past 12 months. This puts Merck stock within the top 19% of all stocks, regardless of industry group.\nShares also have a Relative Strength Rating of 57, reflecting the 12-month performance of Merck stock. This means the pharmaceutical stock ranks beneath the top one-third all stocks in terms of performance.\nIt's also key to watch chart patterns. Merck stock broke out of a flat base with abuy point at 79.33 on Oct. 1, according to MarketSmith.com. But shares fell as much as 7% below their entry on Nov. 30. That triggered a sell signal. Investors are encouraged to sell when a stock is 7%-8% below its entry.\nMerck stock also recently undercut its 50-day and 200-day moving averages. Both are sell signals.\nMerck Stock News: Merck Grabs Covid Deal\nMerck's molnupiravir is now authorized in the U.S., U.K. and Japan.\nIn addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.\nAnalysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.\nBut there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.\nBearishly, the FDA placed a study testing an HIV prevention drug, islatravir, on clinical hold. Several patients showed decreased in key immune cells. Merck and Gilead Sciences(GILD) also decided to stop testing a regimen of islatravir and Gilead's lenacapavir in HIV patients.\nMerck also recently finished acquiring Acceleron.\nIn early March, President Joe Biden announced Merck would helpJohnson & Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.\nIs Merck Stock A Buy Now?\nBased on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.\nThere are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.\nStill, big stocks like Merck can add gains without hitting massive growth streaks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1891,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/696174376"}